Compass Therapeutics (CMPX) has received a new Buy rating, initiated by LifeSci Capital analyst, Charles Zhu.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Charles Zhu has given his Buy rating due to a combination of factors that highlight the potential of Compass Therapeutics’ pipeline. The lead asset, tovecimig, is a bispecific antibody targeting DLL4 and VEGF-A, currently in registrational development for second-line biliary tract cancer (BTC) with prospects for expansion into first-line BTC and other DLL4-positive tumors. This asset is considered clinically de-risked, and its potential market opportunity in the U.S. is estimated to be around $1.4 billion annually, assuming success in ongoing trials.
Additionally, Compass Therapeutics has other promising assets in earlier stages, such as CTX-471 and CTX-8371, which have shown intriguing early clinical proof-of-concept data. The company’s strategic positioning in a fragmented market, along with positive feedback from key opinion leaders in gastrointestinal oncology, supports the potential for practice-changing outcomes. The anticipated success of the COMPANION-002 trial could significantly de-risk further opportunities, reinforcing the positive outlook for Compass Therapeutics.